SCHEMBL2995409

SCHEMBL2995409

Cc1ccc(S(=O)(=O)Nc2ccc(Cl)c(NC3=NC(=O)/C(=C/c4ccc5ncccc5c4)S3)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.55
ALDH1A1 P00352 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
KDM4E B2RXH2 1/20 0.41
ALPL P05186 1/20 0.41
DYRK3 O43781 2/20 0.41
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
NPC1 O15118 1/20 0.39
HSP90AA1 P07900 1/20 0.39
RAB9A P51151 1/20 0.39
ADAM17 P78536 1/20 0.39
KLF5 Q13887 1/20 0.39
PIK3CA P42336 3/20 0.39
PIK3CD O00329 2/20 0.39
PIK3CG P48736 2/20 0.39
PIM1 P11309 1/20 0.39
CSNK2A2 P19784 1/20 0.39
CLK1 P49759 1/20 0.39
CLK3 P49761 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2995411 1.00 LMNA (0.55) LMNAALDH1A1SMN1; SMN2KDM4EALPL
SCHEMBL2987077 0.93 DYRK3 (0.44) LMNAALDH1A1SMN1; SMN2DYRK3PIK3CA
SCHEMBL2987074 0.93 DYRK3 (0.44) LMNAALDH1A1SMN1; SMN2DYRK3PIK3CA
SCHEMBL2999185 0.90 ALDH1A1 (0.42) LMNAALDH1A1SMN1; SMN2DYRK3KMT2A
SCHEMBL2999189 0.90 ALDH1A1 (0.42) LMNAALDH1A1SMN1; SMN2DYRK3KMT2A
SCHEMBL2990583 0.89 DYRK3 (0.44) LMNAALDH1A1SMN1; SMN2DYRK3KMT2A
SCHEMBL2990580 0.89 DYRK3 (0.44) LMNAALDH1A1SMN1; SMN2DYRK3KMT2A
SCHEMBL2997668 0.87 DYRK3 (0.43) LMNAALDH1A1SMN1; SMN2DYRK3KMT2A
SCHEMBL3640892 0.87 DYRK3 (0.43) LMNAALDH1A1SMN1; SMN2KDM4EDYRK3
SCHEMBL2997669 0.87 DYRK3 (0.43) LMNAALDH1A1SMN1; SMN2DYRK3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US claimed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP claimed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO claimed
US-20100184774-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION 2010-07-22 US disclosed
EP-2164494-A1 METHODS OF TREATMENT GlaxoSmithKline LLC (US) 2010-03-24 EP disclosed
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US disclosed
WO-2008150837-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP disclosed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184774-A1 METHODS OF TREATMENT OPRL1, BRCA1, PKD1 LMNA 600/4885ALDH1A1 2461/4885SMN1; SMN2 113/4885
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS HIPK3, HIPK1, HIPK4 LMNA 1257/4885ALDH1A1 4089/4885SMN1; SMN2 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.